A Peptide Just Carried Actinium-225 Into Phase 3. BMS Says It Met the Trial’s Main Goal.

There is a version of peptide medicine that looks almost familiar: a short chain of amino acids binds a receptor and nudges biology in one direction or another.

RYZ101 is not that version.

Its peptide component is used more like a homing device. It searches for a receptor found on many neuroendocrine tumor cells. Attached to that molecular address label is actinium-225, a radioactive isotope whose alpha particles can dump an enormous amount of energy across a distance measured in only a few cell diameters.

The peptide finds the target.

The isotope delivers the violence.

And on October 12, 2026, Bristol Myers Squibb announced that this combination had met the primary endpoint in a randomized Phase 3 trial.

That is an unusually dramatic sentence even by the standards of modern oncology.

The treatment, called RYZ101 (actinium-225 DOTATATE), significantly improved progression-free survival compared with investigator-selected standard therapy in patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors whose disease had already progressed after lutetium-177-based treatment. Bristol Myers described the improvement as statistically significant and clinically meaningful. Detailed efficacy numbers have not yet been released.

That last limitation matters. But so does the milestone.

According to Bristol Myers, these are the first Phase 3 results for an actinium-225-based targeted radiopharmaceutical therapy in any indication.

For people who think of peptides mainly as signaling molecules, hormones, recovery compounds or metabolic drugs, RYZ101 expands the map considerably.

A peptide can also be a delivery vehicle for something close to a microscopic radiation weapon.

First, actinium-225 is not the peptide

The terminology is easy to collapse, so the pieces should be separated.

Actinium-225 is a radioactive isotope. It is not a peptide.

DOTATATE is the targeting component. It is a somatostatin-receptor-binding peptide analogue connected to a chelator called DOTA. That chelator can hold a radioactive metal.

Put them together and the result is 225Ac-DOTATATE.

This architecture is what makes the treatment so striking.

The peptide does not need to kill the cancer cell by itself. Its job is to recognize a biological address. Neuroendocrine tumors frequently express somatostatin receptor type 2, or SSTR2. DOTATATE has been engineered to bind that receptor.

The radioactive payload then changes the purpose of receptor binding.

Instead of asking a receptor to alter a signaling pathway, the molecule can use that receptor as a docking point to bring ionizing radiation close to the tumor cell.

This broader strategy is called peptide receptor radionuclide therapy, or PRRT.

It is not entirely new. Lutetium-177 DOTATATE is already an FDA-approved radiopharmaceutical for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

The leap here is the isotope.

Beta radiation was already impressive. Alpha radiation changes the scale.

Lutetium-177 emits beta particles. Actinium-225 ultimately produces alpha emissions.

That difference is not simply a matter of one radioactive element replacing another.

Alpha particles have very high linear energy transfer: they deposit a large amount of energy over a very short track. Reviews of targeted alpha therapy describe tissue penetration on the order of only a few cell diameters. Actinium-225 also has a roughly 10-day half-life and generates multiple alpha emissions through its decay chain.

The physical idea is almost absurdly elegant.

If a radioactive payload circulated without useful targeting, that destructive power would be a liability.

If a targeting molecule can concentrate it around receptor-rich tumor tissue, the same short range becomes part of the attraction: deliver intense energy locally while limiting how far an individual alpha particle travels.

That does not mean surrounding normal tissue is automatically safe. Radiopharmaceutical therapy still raises difficult questions about where the drug accumulates, organ dose, marrow toxicity, kidney exposure, radioactive daughter products, manufacturing, contamination control and long-term safety.

But the engineering principle is remarkable.

Medicine has taken a receptor-binding peptide and asked it to perform the molecular equivalent of target acquisition.

The Phase 3 result matters because these patients had already received radiopharmaceutical therapy

ACTION-1 is not testing RYZ101 in treatment-naive patients.

The trial enrolled patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors whose disease had progressed after lutetium-177-based therapy.

That makes the question more interesting.

These tumors had already encountered a receptor-targeted radioactive treatment. RYZ101 is attempting to use a related targeting logic while changing the radioactive payload.

The randomized comparator was investigator’s choice of standard care, including high-dose or more frequent long-acting somatostatin analogues, everolimus or sunitinib.

At a planned interim analysis, BMS reported that RYZ101 achieved a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review.

The company has not yet published the magnitude of that improvement.

We therefore do not know from the topline announcement how many additional months of median progression-free survival were gained, what the hazard ratio was, how different subgroups performed, or the full adverse-event distribution.

Those details will determine how large this advance really is.

Still, a randomized Phase 3 study reaching its primary endpoint is a much higher evidentiary threshold than a promising mouse experiment, an imaging study or a small uncontrolled case series.

The optimism should be aimed at what actually happened.

The platform survived a serious test.

The peptide is doing something peptide enthusiasts rarely talk about

The popular peptide conversation tends to orbit familiar categories: appetite, growth hormone signaling, injury recovery, inflammation, pigmentation, sleep, libido, mitochondrial signaling.

RYZ101 belongs to a different conceptual universe.

Here the peptide is not primarily interesting because of the downstream biological signal it generates.

It is interesting because of where it goes.

That distinction could become increasingly important in peptide drug development.

A peptide’s value may lie not only in what it tells a cell to do, but in what it can carry to that cell.

Radioisotopes are one example. Other payload strategies across medicine include cytotoxic compounds, imaging agents and molecular cargo attached to targeting ligands.

The peptide becomes infrastructure.

That is a very different way to think about peptide therapeutics.

A short amino-acid chain attached to a nuclear-physics problem

The elegance at the molecular level should not obscure the logistical challenge.

Actinium-225 has historically been difficult to produce at the scale demanded by widespread clinical use. Recent reviews continue to identify radionuclide supply, radiochemistry, dosimetry and manufacturing standardization as major constraints on targeted alpha therapy.

That means RYZ101 is not simply a drug-development story.

It is also a manufacturing story, an isotope-supply story, a nuclear-medicine story and a hospital-operations story.

Bristol Myers Squibb did not buy RayzeBio for a peptide sequence alone. The company paid approximately $4.1 billion for RayzeBio in 2024, gaining its actinium-based radiopharmaceutical platform, development pipeline and manufacturing capability.

At the time, that acquisition could be read as a large pharmaceutical company buying an expensive hypothesis.

The October 2026 Phase 3 announcement does not prove the entire platform will work across cancers. But it does make the original bet look substantially less hypothetical.

The lead asset has now produced a positive late-stage signal.

This did not appear from nowhere

The peptide-radionuclide concept has a history.

Somatostatin is itself a peptide hormone. Synthetic somatostatin analogues were developed to bind somatostatin receptors more usefully in clinical settings. DOTATATE combines a receptor-targeting peptide analogue with a chelator that can hold a radionuclide.

That architecture allowed one molecular targeting system to become adaptable.

Change the radionuclide, and the physical behavior of the treatment can change while the receptor-targeting logic remains recognizable.

The FDA approved lutetium-177 DOTATATE for adults with SSTR-positive GEP-NETs in 2018 and expanded approval to patients aged 12 and older in 2024.

Actinium-225 DOTATATE is attempting to push the same broad targeting concept into alpha therapy.

Early clinical literature had already suggested that 225Ac-DOTATATE could produce responses in advanced SSTR-positive neuroendocrine tumors, including after prior beta-emitter PRRT. A 2025 review of several alpha-emitting PRRT approaches summarized seven studies totaling 150 patients and reported disease-control signals, while emphasizing that Phase 3 evidence was still needed. Those studies included different radionuclides and treatments, not just RYZ101 or actinium-225 DOTATATE.

Now the first announced Phase 3 result has arrived.

That does not make every earlier estimate correct. It changes the evidentiary category of the conversation.

Why “radioactive peptide” is not just a headline trick

The phrase sounds sensational because the underlying technology is sensational.

The molecule combines three different disciplines:

1. Peptide biology supplies the receptor-seeking component.
2. Coordination chemistry supplies a cage that can hold a metal radionuclide.
3. Nuclear physics supplies a payload capable of depositing lethal energy over microscopic distance.

The treatment only works as intended if these layers cooperate.

A targeting peptide without an effective payload may locate the tumor without doing enough damage.

A powerful isotope without useful targeting may expose normal tissue unnecessarily.

A good ligand and a good isotope with poor chelation or unstable manufacturing can create an entirely different problem.

RYZ101 is therefore not evidence that peptides are inherently miraculous. It is evidence that peptides can become components in systems far more sophisticated than the usual “peptide binds receptor, receptor changes signaling” story.

That is the part worth being surprised by.

The remaining unknowns are important, not deflating

BMS has disclosed the direction of the Phase 3 result, not the detailed dataset.

We still need to see the actual progression-free-survival curves, hazard ratio, duration of follow-up, response data, organ-specific toxicities, hematologic effects, dose modifications, discontinuations, quality-of-life results and eventually overall survival.

BMS said safety was consistent with the known RYZ101 profile. In the company’s description of a prior Phase 1b cohort of 17 previously lutetium-treated patients, there were no treatment-related serious adverse events or discontinuations due to adverse events. That does not mean there were no severe adverse events: earlier trial reporting included grade 3-or-higher anemia and lymphopenia. That is useful context, not a substitute for the larger Phase 3 safety table.

Alpha emitters also introduce issues that ordinary peptide pharmacology does not solve: daughter-radionuclide redistribution, radiation protection, waste handling and isotope availability.

A successful drug has to survive physics, biology, manufacturing and medicine at the same time.

That is exactly why the positive trial is so interesting.

A surprisingly literal form of precision medicine

“Precision medicine” can become an empty phrase.

RYZ101 makes it unusually concrete.

Find a receptor enriched on the tumor.

Use a peptide to bind it.

Attach a chelator.

Load the chelator with an isotope.

Let the isotope decay.

Exploit the fact that an alpha particle travels only a microscopic distance while carrying enough energy to cause severe DNA damage.

Then test whether that machinery actually delays cancer progression in people.

According to Bristol Myers Squibb, the answer at the Phase 3 interim analysis was yes.

Not “the tumor disappeared.”

Not “cancer has been solved.”

Not “actinium-225 is now approved.”

The result was narrower and more important: RYZ101 improved progression-free survival enough for the randomized trial to meet its primary endpoint.

That is a real clinical threshold.

One of the strangest frontiers in peptide medicine just became harder to ignore

The peptide field is often discussed as though its future depends entirely on discovering new signaling sequences.

RYZ101 suggests another future.

Existing receptor-binding biology can be turned into a transportation network for entirely different forms of therapy.

In this case, the cargo is radioactive.

And not mildly so.

The molecular package is trying to use a peptide’s receptor specificity to put an alpha-emitting isotope close enough to a cancer cell that nuclear decay becomes therapeutically useful.

That is such an extreme combination of disciplines that it almost sounds like speculative medicine.

It is now the subject of a positive Phase 3 readout.

The detailed results still need to justify the enthusiasm. Regulatory review still lies ahead. RYZ101 remains investigational. Supply and safety questions remain real.

But if the full dataset supports the topline announcement, peptide research may have just crossed one of its most unusual boundaries yet.

The peptide is no longer merely the message. It can be the guidance system.

And this time, what it is guiding is actinium-225.

---

Editorial note: RYZ101 is an investigational radiopharmaceutical, not an approved treatment. Actinium-225 is a radioactive isotope, not a peptide. The peptide-based targeting component is DOTATATE. Bristol Myers Squibb has announced positive topline Phase 3 results, but detailed efficacy and safety data have not yet been presented publicly. This article is educational reporting, not medical advice.

Review disclosure: This article was prepared with AI assistance and checked against the linked sources by AI. It has not yet undergone independent professional medical review. AI verification is not professional medical review.